169 related articles for article (PubMed ID: 23707254)
1. Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.
Darvesh S; Macdonald IR; Martin E
Bioorg Med Chem Lett; 2013 Jul; 23(13):3822-5. PubMed ID: 23707254
[TBL] [Abstract][Full Text] [Related]
2. Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine.
Darvesh S; McDonald RS; Darvesh KV; Mataija D; Conrad S; Gomez G; Walsh R; Martin E
Bioorg Med Chem; 2007 Oct; 15(19):6367-78. PubMed ID: 17681768
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivatives.
Darvesh S; McDonald RS; Penwell A; Conrad S; Darvesh KV; Mataija D; Gomez G; Caines A; Walsh R; Martin E
Bioorg Med Chem; 2005 Jan; 13(1):211-22. PubMed ID: 15582466
[TBL] [Abstract][Full Text] [Related]
4. N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
González-Muñoz GC; Arce MP; López B; Pérez C; Romero A; del Barrio L; Martín-de-Saavedra MD; Egea J; León R; Villarroya M; López MG; García AG; Conde S; Rodríguez-Franco MI
Eur J Med Chem; 2011 Jun; 46(6):2224-35. PubMed ID: 21420206
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
Schwarthoff S; Tischer N; Sager H; Schätz B; Rohrbach MM; Raztsou I; Robaa D; Gaube F; Arndt HD; Winckler T
Bioorg Med Chem; 2021 Sep; 46():116355. PubMed ID: 34391122
[TBL] [Abstract][Full Text] [Related]
6. Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants.
Darvesh S; Pottie IR; Darvesh KV; McDonald RS; Walsh R; Conrad S; Penwell A; Mataija D; Martin E
Bioorg Med Chem; 2010 Mar; 18(6):2232-2244. PubMed ID: 20181484
[TBL] [Abstract][Full Text] [Related]
7. Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
Tasso B; Catto M; Nicolotti O; Novelli F; Tonelli M; Giangreco I; Pisani L; Sparatore A; Boido V; Carotti A; Sparatore F
Eur J Med Chem; 2011 Jun; 46(6):2170-84. PubMed ID: 21459491
[TBL] [Abstract][Full Text] [Related]
8. The exploration of thienothiazines as selective butyrylcholinesterase inhibitors.
Karlsson D; Fallarero A; Brunhofer G; Mayer C; Prakash O; Mohan CG; Vuorela P; Erker T
Eur J Pharm Sci; 2012 Aug; 47(1):190-205. PubMed ID: 22683890
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore based 3DQSAR of phenothiazines as specific human butyrylcholinesterase inhibitors for treatment of Alzheimer's disease.
Kundaikar HS; Agre NP; Degani MS
Curr Comput Aided Drug Des; 2014; 10(4):335-48. PubMed ID: 25794302
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of butyrylcholinesterase by singlet oxygen-generated melatonin derivatives.
Moleda Z; Wojtasiewicz K; Panasiewicz M; Czarnocki Z
J Pineal Res; 2010 Aug; 49(1):55-9. PubMed ID: 20459459
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of butyrylcholinesterase by phenothiazine derivatives.
Debord J; Merle L; Bollinger JC; Dantoine T
J Enzyme Inhib Med Chem; 2002 Jun; 17(3):197-202. PubMed ID: 12443046
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors.
Razavi SF; Khoobi M; Nadri H; Sakhteman A; Moradi A; Emami S; Foroumadi A; Shafiee A
Eur J Med Chem; 2013 Jun; 64():252-9. PubMed ID: 23644208
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of phenserine analogues and evaluation of their cholinesterase inhibitory activities.
Shinada M; Narumi F; Osada Y; Matsumoto K; Yoshida T; Higuchi K; Kawasaki T; Tanaka H; Satoh M
Bioorg Med Chem; 2012 Aug; 20(16):4901-14. PubMed ID: 22831800
[TBL] [Abstract][Full Text] [Related]
14. Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment.
Musilek K; Komloova M; Holas O; Hrabinova M; Pohanka M; Dohnal V; Nachon F; Dolezal M; Kuca K
Eur J Med Chem; 2011 Feb; 46(2):811-8. PubMed ID: 21236521
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.
Xie SS; Wang XB; Li JY; Yang L; Kong LY
Eur J Med Chem; 2013 Jun; 64():540-53. PubMed ID: 23685572
[TBL] [Abstract][Full Text] [Related]
16. Tacrine based human cholinesterase inhibitors: synthesis of peptidic-tethered derivatives and their effect on potency and selectivity.
Butini S; Guarino E; Campiani G; Brindisi M; Coccone SS; Fiorini I; Novellino E; Belinskaya T; Saxena A; Gemma S
Bioorg Med Chem Lett; 2008 Oct; 18(19):5213-6. PubMed ID: 18786825
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
Yu Q; Holloway HW; Utsuki T; Brossi A; Greig NH
J Med Chem; 1999 May; 42(10):1855-61. PubMed ID: 10346939
[TBL] [Abstract][Full Text] [Related]
18. 2-(2-indolyl-)-4(3H)-quinazolines derivates as new inhibitors of AChE: design, synthesis, biological evaluation and molecular modelling.
Li Z; Wang B; Hou JQ; Huang SL; Ou TM; Tan JH; An LK; Li D; Gu LQ; Huang ZS
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):583-92. PubMed ID: 22380775
[TBL] [Abstract][Full Text] [Related]
19. [Study of the relationship between neuroleptic activity and anticholinesterase property of various phenothiazine derivatives].
Legheand J; Cuisinaud G; Solal-Seccia M; Cier A
Ann Pharm Fr; 1973; 31(9):613-22. PubMed ID: 4793704
[No Abstract] [Full Text] [Related]
20. Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability.
Dillon GP; Gaynor JM; Khan D; Carolan CG; Ryder SA; Marquez JF; Reidy S; Gilmer JF
Bioorg Med Chem; 2010 Feb; 18(3):1045-53. PubMed ID: 20093035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
